Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/genetic-counseling-and-genetic-testing-in-the-preoperative-evaluation-kysb10KCkH
References (69)
-
A. Finch, M. Beiner, J. Lubiński, H. Lynch, P. Møller, B. Rosen, Joan Murphy, P. Ghadirian, E. Friedman, W. Foulkes, C. Kim-sing, T. Wagner, N. Tung, F. Couch, D. Stoppa-Lyonnet, P. Ainsworth, M. Daly, B. Pasini, R. Gershoni-baruch, C. Eng, O. Olopade, Jane McLennan, B. Karlan, J. Weitzel, P. Sun, S. Narod (2006)
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.JAMA, 296 2
-
M. Litwiniuk, K. roznowski, V. Filas, D. Godlewski, M. Stawicka, R. Kaleta, J. Bręborowicz (2008)
Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriersBMC Cancer, 8
-
J. Forbes, J. Cuzick, A. Buzdar, A. Howell, J. Tobias, M. Baum (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.The Lancet. Oncology, 9 1
-
L. Pierce, K. Phillips, K. Griffith, S. Buys, D. Gaffney, M. Moran, B. Haffty, M.K.B. Ben-David, B. Kaufman, J. Garber, S. Merajver, J. Balmaña, A. Meirovitz, S. Domchek (2010)
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyBreast Cancer Research and Treatment, 121
-
P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, Peter Mortimer, H. Swaisland, A. Lau, M. O’Connor, A. Ashworth, J. Carmichael, S. Kaye, J. Schellens, J. Bono (2009)
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.The New England journal of medicine, 361 2
-
Benjamin Smith, D. Arthur, T. Buchholz, B. Haffty, C. Hahn, P. Hardenbergh, T. Julian, L. Marks, D. Todor, F. Vicini, T. Whelan, J. White, J. Wo, J. Harris (2009)
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).Journal of the American College of Surgeons, 209 2
-
P. Wysocki, Konstanty Korski, K. Lamperska, J. Zaluski, A. Mackiewicz (2008)
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations.Medical science monitor : international medical journal of experimental and clinical research, 14 7
-
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, S. Narod, J. Lubiński, The Consortium (2008)
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancersBreast Cancer Research and Treatment, 108
-
A. Buzdar, A. Howell, J. Cuzick, C. Wale, W. Distler, G. Hoctin-Boes, J. Houghton, G. Locker, Nabholtz Jm (2006)
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.The Lancet. Oncology, 7 8
-
J Tyrer, SW Duffy, J Cuzick (2004)
A breast cancer prediction model incorporating familial and personal risk factorsStat Med, 23
-
T. Rebbeck, H. Lynch, S. Neuhausen, S. Narod, L. Veer, J. Garber, G. Evans, C. Isaacs, M. Daly, E. Matloff, O. Olopade, B. Weber (2002)
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.The New England journal of medicine, 346 21
-
M. Wevers, M. Ausems, S. Verhoef, E. Bleiker, D. Hahn, F. Hogervorst, R. Luijt, H. Valdimarsdottir, R. Hillegersberg, E. Rutgers, N. Aaronson (2011)
Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: Design of a multicenter randomized clinical trialBMC Cancer, 11
-
A. Fedier, R. Steiner, V. Schwarz, Lenka Lenherr, U. Haller, D. Fink (2003)
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.International journal of oncology, 22 5
-
Beroukas Ernestos, Pandis Nikolaos, G. Koulis, Rizou Eleni, Beroukas Konstantinos, Giatromanolaki Alexandra, K. Michael (2010)
Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay.International journal of radiation oncology, biology, physics, 76 4
-
T. Flaig, C. Tangen, M. Hussain, W. Stadler, D. Raghavan, E. Crawford, L. Glodé (2008)
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 9
-
W. Foulkes, J. Goffin, J. Brunet, L. Bégin, N. Wong, P. Chappuis (2002)
Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.Journal of the National Cancer Institute, 94 19
-
T. Walsh, S. Casadei, Kathryn Coats, E. Swisher, S. Stray, Jake Higgins, Kevin Roach, Jessica Mandell, Ming Lee, S. Ciernikova, L. Foretova, P. Souček, M. King (2006)
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.JAMA, 295 12
-
L. Chen, B. Crawford, Jane McLennan, E. Hwang, R. Foster, C. Powell (2008)
Combining risk-reducing salpingo-oophorectomy with mastectomy and reconstructive surgery in BRCA1 and BRCA2 mutation carrierJournal of Clinical Oncology, 26
-
T. Rebbeck, N. Kauff, S. Domchek (2009)
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation CarriersJNCI Journal of the National Cancer Institute, 101
-
S. Alkhayyat, Muhammad Khan, Tauseef Ahmad, Haroon, Huma Tariq, M. Baig (2022)
A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genesMedicine, 101
-
U. Force (2005)
Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation StatementAnnals of Internal Medicine, 143
-
B. Fisher, J. Bryant, J. Dignam, D. Wickerham, E. Mamounas, Edwin Fisher, R. Margolese, L. Nesbitt, S. Paik, T. Pisansky, N. Wolmark (2002)
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 20
-
G. Mitchell, A. Ardern-jones, M. Mchir, R. Taylor, R. Eeles (2004)
A paradox: urgent BRCA genetic testingFamilial Cancer, 1
-
Eun-Ha Lee, Sue-Kyung Park, Boyoung Park, Sungwan Kim, M. Lee, S. Ahn, B. Son, K. Yoo, D. Kang, Kohbra Group, Korean Society (2010)
Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysisBreast Cancer Research and Treatment, 122
-
Katherine Geer, M. Ropka, W. Cohn, Susan Jones, S. Miesfeldt (2001)
Factors Influencing Patients' Decisions to Decline Cancer Genetic Counseling ServicesJournal of Genetic Counseling, 10
-
D. Braithwaite, J. Emery, F. Walter, A. Prevost, S. Sutton (2005)
Psychological Impact of Genetic Counseling for Familial Cancer: A Systematic Review and Meta-AnalysisFamilial Cancer, 5
-
J. Boughey, T. Hoskin, A. Degnim, T. Sellers, Joanne Johnson, M. Kasner, L. Hartmann, M. Frost (2010)
Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast CancerAnnals of Surgical Oncology, 17
-
V. Cappelletti, S. Veneroni, D. Coradini, S. Oriana, G. Tomasic, M. Younes, M. Daidone (2003)
Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.Journal of the National Cancer Institute, 95 8
-
Grace Wang, M. Beattie, N. Ponce, K. Phillips (2011)
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counselingGenetics in Medicine, 13
-
M. Schwartz, C. Lerman, Barbara Brogan, B. Peshkin, C. Halbert, T. Demarco, W. Lawrence, D. Main, C. Finch, C. Magnant, M. Pennanen, T. Tsangaris, S. Willey, C. Isaacs (2004)
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 10
-
M. Bredel (2008)
Nomograms as clinicobiological predictors of survival in glioblastoma.The Lancet. Oncology, 9 1
-
L. Pierce, A. Levin, T. Rebbeck, M. Ben-David, E. Friedman, L. Solin, E. Harris, D. Gaffney, B. Haffty, L. Dawson, S. Narod, I. Olivotto, A. Eisen, T. Whelan, O. Olopade, C. Isaacs, S. Merajver, J. Wong, J. Garber, B. Weber (2006)
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 16
-
B. Haffty, E. Harrold, Atif Khan, P. Pathare, Tanya Smith, B. Turner, P. Glazer, B. Ward, D. Carter, E. Matloff, A. Bale, Mayra Alvarez-Franco (2002)
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 statusThe Lancet, 359
-
(2002)
BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. 27th Congress of the European Society for Medical Oncology -
A. Antoniou, P. Pharoah, G. McMullan, N. Day, Michael Stratton, J. Peto, B. Ponder, D. Easton (2002)
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genesBritish Journal of Cancer, 86
-
R. Hendrick (2010)
Radiation doses and cancer risks from breast imaging studies.Radiology, 257 1
-
N. Kauff, R. Barakat (2007)
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 20
-
M. Schwartz, C. Lerman, Barbara Brogan, B. Peshkin, C. Isaacs, T. Demarco, C. Halbert, M. Pennanen, C. Finch (2005)
Utilization of BRCA1/BRCA2 Mutation Testing in Newly Diagnosed Breast Cancer PatientsCancer Epidemiology Biomarkers & Prevention, 14
-
C. Garcia-Etienne, M. Barile, O. Gentilini, E. Botteri, N. Rotmensz, A. Sagona, G. Farante, V. Galimberti, A. Luini, P. Veronesi, B. Bonanni (2009)
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?Annals of Surgical Oncology, 16
-
R. Love, J. Philips (2002)
Oophorectomy for breast cancer: history revisited.Journal of the National Cancer Institute, 94 19
-
(2008)
Arimidex, Tamoxifen Alone -
B. Meiser, Jennifer Irle, E. Lobb, K. Barlow-Stewart (2008)
Assessment of the Content and Process of Genetic Counseling: A Critical Review of Empirical StudiesJournal of Genetic Counseling, 17
-
C. Antoine, F. Liebens, B. Carly, A. Pastijn, S. Neusy, S. Rozenberg (2006)
Safety of hormone therapy after breast cancer: a qualitative systematic review.Human reproduction, 22 2
-
J. Cuzick (2004)
A breast cancer prediction model incorporating familial and personal risk factorsHereditary Cancer in Clinical Practice, 10
-
D. Berry, G. Parmigiani, Juana Sanchez, J. Schildkraut, Eric Winer (1997)
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.Journal of the National Cancer Institute, 89 3
-
Pam Das, Adeeba Kamarulzaman, Tony Mok, John O'Grady (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialBreast Diseases: A Year Book Quarterly, 22
-
J. Dungan (2011)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityYearbook of Obstetrics, Gynecology and Women's Health, 2011
-
(2011)
CancerGene, 2011 http://www4.utsouthwestern.edu/ breasthealth/cagene -
A. Hubert, Bela Mali, T. Hamburger, Y. Rottenberg, B. Uziely, T. Peretz, L. Kadouri (2008)
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancerFamilial Cancer, 8
-
SA Narod, JS Brunet, P Ghadirian (2000)
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study GroupLancet, 356
-
B. Stordal, N. Pavlakis, R. Davey (2007)
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.Cancer treatment reviews, 33 8
-
J. Berliner, A. Fay (2007)
Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic CounselorsJournal of Genetic Counseling, 16
-
K. Nordin, A. Roshanai, Cathrine Bjorvatn, Katharina Wollf, E. Mikkelsen, I. Bjelland, G. Kvale (2011)
Is genetic counseling a stressful event?Acta Oncologica (Stockholm, Sweden), 50
-
Kathryn Schlich-Bakker, H. Kroode, C. Wárlám-Rodenhuis, J. Bout, M. Ausems (2007)
Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancerGenetics in Medicine, 9
-
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, R. Dent, J. Lubiński, S. Narod (2010)
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
-
T. Byrski, T. Huzarski, R. Dent, J. Gronwald, D. Zuziak, C. Cybulski, J. Kładny, B. Górski, J. Lubiński, S. Narod (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 115
-
S. Narod, J. Brunet, P. Ghadirian, M. Robson, K. Heimdal, S. Neuhausen, D. Stoppa-Lyonnet, C. Lerman, B. Pasini, P. Rios, B. Weber, H. Lynch (2000)
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 356
-
J. Reichelt, K. Heimdal, P. Møller, A. Dahl (2004)
BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sampleFamilial Cancer, 3
-
BD Smith, DW Arthur, TA Buchholz (2009)
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO)Int J Radiat Oncol Biol Phys, 74
-
F. Liebens, B. Carly, A. Pastijn, S. Rozenberg (2007)
Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006.European journal of cancer, 43 2
-
J. Cuzick, I. Šestak, M. Baum, A. Buzdar, A. Howell, M. Dowsett, J. Forbes (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.The Lancet. Oncology, 11 12
-
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
-
P. Chappuis, J. Goffin, N. Wong, C. Perret, P. Ghadirian, P. Tonin, W. Foulkes (2002)
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancerJournal of Medical Genetics, 39
-
S. Domchek, T. Friebel, C. Singer, D. Evans, H. Lynch, C. Isaacs, J. Garber, S. Neuhausen, E. Matloff, R. Eeles, G. Pichert, Laura t'veer, N. Tung, J. Weitzel, F. Couch, W. Rubinstein, P. Ganz, M. Daly, O. Olopade, G. Tomlinson, J. Schildkraut, J. Blum, T. Rebbeck (2010)
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.JAMA, 304 9
-
M. Graeser, C. Engel, K. Rhiem, D. Gadzicki, U. Bick, K. Kast, U. Froster, B. Schlehe, A. Bechtold, N. Arnold, S. Preisler‐Adams, C. Nestle-Kraemling, Mohammad Zaino, M. Loeffler, M. Kiechle, A. Meindl, D. Varga, R. Schmutzler (2009)
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 35
-
J. Gronwald, N. Tung, W. Foulkes, K. Offit, R. Gershoni, M. Daly, C. Kim-sing, H. Olsson, P. Ainsworth, A. Eisen, H. Saal, E. Friedman, O. Olopade, M. Osborne, J. Weitzel, H. Lynch, P. Ghadirian, J. Lubiński, P. Sun, S. Narod (2006)
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An updateInternational Journal of Cancer, 118
-
S. Vadaparampil, G. Quinn, J. Lee, T. Malo, Xiuhua Zhao, C. Miree, Jennifer Brzosowicz (2011)
Satisfaction with Physician Recommendation for and Information About Genetic Counseling Among Breast Cancer PatientsThe Breast Journal, 17
-
T. Rebbeck, T. Friebel, T. Wagner, Henry Lynch, Judy Garber, M. Daly, C. Isaacs, O. Olopade, S. Neuhausen, R. Eeles, D. Evans, G. Tomlinson, E. Matloff, S. Narod, A. Eisen, S. Domchek, K. Armstrong, Barbara Weber (2005)
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
-
I. Bedrosian, Chung-Yuan Hu, G. Chang (2010)
Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.Journal of the National Cancer Institute, 102 6
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Internal Medicine; Surgical Oncology; Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-012-0071-y
- Publisher site
- See Article on Publisher Site
Abstract
Breast cancers arising in the context of germline BRCA gene mutation have unique biological features that must be considered during treatment planning. Breast conserving surgery is an acceptable option in highly motivated women who are fully informed about the risks of ipsilateral breast tumor recurrence and contralateral breast cancer. Partial breast irradiation is not recommended for these women. Concurrent bilateral salpingo-oophorectomy should be considered. BRCA1-associated breast cancer may be resistant to taxanes, but appears highly sensitive to platinum agents and to PARP inhibitors. Preoperative genetic testing can be accomplished with short turn around times and does not increase patient anxiety. Inclusion of a professional genetic counselor in the management team is essential. BRCA gene mutation status is emerging as an important prognostic and predictive factor for breast cancer patients. Preoperative genetic counseling and testing is recommended for women likely to carry a BRCA gene mutation.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Feb 11, 2012